In fact, the upregulation of METTL13 has been detected in many cancers and is associated with worse prognoses, such as breast cancer, head and neck squamous cell carcinoma, nasopharyngeal carcinoma, and gastric cancer [33–36]. Here, METTL13 is linked to breast carcinoma.